Live Breaking News & Updates on Trinav infusion system

Stay updated with breaking news from Trinav infusion system. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

TriSalus Reports Q4 and Full Year 2023 Financial Results and Business Update

Reported revenues of $5.7 million in 4Q23, up 77% over prior year



Full year revenues of $18.5 million, up 49% over prior year



Gross Margin of 90% in 4Q23 and 86% for full year



CMS. ....

Texas , United-states , Mary-szela , Intrahepatic-cholangiocarcinoma , Trisalus-life-sciences , Centers-for-medicare-medicaid-services , Linkedin , Academic-oncology-centers , University-of-texas-md-anderson-cancer-center , Nasdaq , Company-annual-report-on-form , Twitter

333,333 Shares in TriSalus Life Sciences, Inc. (NASDAQ:TLSIW) Acquired by Deerfield Management Company L.P. Series C

Deerfield Management Company L.P. Series C acquired a new stake in shares of TriSalus Life Sciences, Inc. (NASDAQ:TLSIW – Free Report) in the third quarter, HoldingsChannel reports. The institutional investor acquired 333,333 shares of the company’s stock, valued at approximately $127,000. Separately, Context Capital Management LLC purchased a new position in TriSalus Life Sciences in […] ....

Quarter-for-trisalus-life-sciences , News-ratings-for-trisalus-life-sciences-daily , Trisalus-life-sciences-inc , Trisalus-life-sciences , Deerfield-management-companylp-series , Trisalus-life-sciences-company-profile , Context-capital-management , Trisalus-life-sciences-stock-performance , Nasdaq , Free-report , Salus-life-sciences

Deerfield Management Company L.P. Series C Makes New $127,000 Investment in TriSalus Life Sciences, Inc. (NASDAQ:TLSIW)

Deerfield Management Company L.P. Series C bought a new stake in TriSalus Life Sciences, Inc. (NASDAQ:TLSIW – Free Report) in the 3rd quarter, according to its most recent filing with the SEC. The fund bought 333,333 shares of the company’s stock, valued at approximately $127,000. Separately, Context Capital Management LLC acquired a new position in […] ....

Trisalus-life-sciences-inc , Quarter-for-trisalus-life-sciences , News-ratings-for-trisalus-life-sciences-daily , Nasdaq , Trisalus-life-sciences , Deerfield-management-companylp-series , Context-capital-management , Trisalus-life-sciences-stock-performance , Free-report , Salus-life-sciences , Trinav-infusion-system

Deerfield Management Company L.P. Series C Makes New $127,000 Investment in TriSalus Life Sciences, Inc. (NASDAQ:TLSIW)

Deerfield Management Company L.P. Series C bought a new stake in TriSalus Life Sciences, Inc. (NASDAQ:TLSIW – Free Report) in the 3rd quarter, according to its most recent filing with the SEC. The fund bought 333,333 shares of the company’s stock, valued at approximately $127,000. Separately, Context Capital Management LLC acquired a new position in […] ....

Trisalus-life-sciences-inc , Quarter-for-trisalus-life-sciences , News-ratings-for-trisalus-life-sciences-daily , Nasdaq , Trisalus-life-sciences , Deerfield-management-companylp-series , Context-capital-management , Trisalus-life-sciences-stock-performance , Free-report , Salus-life-sciences , Trinav-infusion-system

Late-Breaking Phase 1 Liver Metastasis Data from TriSalus Presented at SITC 2023 Supports Development of Innovative Immuno-oncology Approach for Liver and Pancreas Indications

04.11.2023 - TriSalus Life Sciences Inc., (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, today presented additional Phase 1 clinical data . Seite 1 ....

Texas , United-states , Sapna-patel , Stevenc-katz , Trisalus-life-sciences-inc , University-of-texas-md-anderson-cancer-center , Society-of-immunotherapy , Nasdaq , Trinav-infusion-system , Progression-free-survival , Disease-control-rate , Chief-medical-officer